NASDAQ:KLDO Kaleido Biosciences (KLDO) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 10/9/2026 02:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Kaleido Biosciences Stock (NASDAQ:KLDO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kaleido Biosciences alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.20Volume11,167 shsAverage Volume2,281 shsMarket Capitalization$4.26 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kaleido Biosciences, Inc. was a biotechnology company focused on developing microbiome metabolic therapies. Its approach used synthetic glycans—nonliving, carbohydrate-based compounds designed to selectively influence the activity of microorganisms in the gastrointestinal tract and potentially address disease through changes in microbiome function. The company’s development programs included KB109, an investigational microbiome metabolic therapy studied in several clinical settings, including gastrointestinal disorders and infectious diseases. Kaleido also explored applications of its platform in areas such as immunology and oncology. Its programs were investigational and had not been established as approved treatments. Kaleido Biosciences was founded in 2015 and based in Massachusetts. After clinical and strategic challenges, the company announced plans to wind down operations and discontinue development activities. As a result, it is generally regarded as a former operating biotechnology company rather than an active commercial healthcare business.AI Generated. May Contain Errors. Read More Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLDO Stock News HeadlinesKaleido Biosciences Insider Trading Activity | OTC:KLDO | BenzingaApril 20, 2026 | benzinga.comKaleido Biosciences Inc.February 18, 2026 | marketwatch.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 11 at 1:00 AM | Banyan Hill Publishing (Ad)Kaleido Biosciences Inc (KLDO)April 10, 2025 | uk.investing.comSyniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Fourth Straight YearDecember 11, 2024 | finance.yahoo.comBICS, Cellusys, Comfone, Mobileum, Syniverse, Telefónica Global Solutions & TOMIA MACH Named Champion Roaming Vendors by Kaleido IntelligenceNovember 25, 2024 | markets.businessinsider.comKaleido Biosciences (OTC:KLDO) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comKaleido announces the appointment of RBC Investor Services as the new custodian of its scholarship plansOctober 1, 2024 | ca.finance.yahoo.comSee More Headlines KLDO Stock Analysis - Frequently Asked Questions How have KLDO shares performed this year? Kaleido Biosciences' stock was trading at $0.0001 at the beginning of the year. Since then, KLDO stock has increased by 0.0% and is now trading at $0.0001. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) posted its quarterly earnings data on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The business earned $0.10 million during the quarter, compared to analysts' expectations of $0.25 million. When did Kaleido Biosciences IPO? Kaleido Biosciences (KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), Compass Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB). Company Calendar Last Earnings11/01/2021Today10/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:KLDO CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees76Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$4.26 thousand OptionableNot Optionable Beta-0.06 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:KLDO) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
